Market Potential

Sepsis affects 50 million people worldwide each year, whereof 11 million die¹. Today, sepsis is the most costly condition to treat at American hospitals, with a yearly cost of 62 BUSD for treatment and care². The high number of deaths in combination with the high costs for the hospitals indicate a great potential market for a treatment which can address the life-threatening combination of coagulation and inflammation, which is the cause of sepsis.

In the coming ten years, both the number of sepsis cases and the market share for immunomodulating treatments will increase. The global market for sepsis treatements is expected to grow from 3.5 BUSD in 2020 to 7.5 BUSD in 2030 for the seven largest markets in the world (USA, France, Germany, Great Britain, Italy, Spain and Japan)³. Aptahem’s patent rights for Apta-1 as a therapeutic treatment covers these markets until and including 2038.

Aptahem’s assumptions indicate that Apta-1 can capture around15% in a 4 year period of the severe sepsis market.